Sechenov University in Russia claimed that the vaccine trials for coronavirus disease (COVID-19) on Volunteers had been completed successfully. The Sechnevov First Moscow State Medical University on their website said that they had begun clinical trials on June 18. This Vaccine was Fabricated by Russia's Gamaleya Institute of Epidemiology and Microbiology. Also Read: China brings a new virus threat for the world; The G4 virus The Russian ministry of health authorized the trial to run on June 16. The Permission for the trial was given on June 16 by the Russian Ministry of Health. The first group of volunteers would be discharged by Wednesday, which is by July 15, and the second by July 20, the university said. How the trials proceeded for Coronavirus Vaccine? On June 18, the first group of 18 fit volunteers got vaccinated. At the same time, the second group, which consisted of 20 volunteers, received the vaccine on June 23. The procedures took place at the Practical Research Centre for Interventional Cardiovasology. Volunteers were of the age group from 18 to 65, which included males and females. The volunteers were given a lyophilized vaccine or a powder from which a solution is prepared for intramuscular injection. Symptoms such as headache and elevated body temperature came to notice. However, the symptoms resolved entirely within a day with vaccine administration. The isolation period that the volunteers spent were of 28 days after they received the vaccine to protect them from getting affected by any other infections. After getting discharged, they will be monitored for more than six months. There is no judgment on whether this vaccine is useful for the commercial stage. There are almost 21 vaccines that are currently running under critical trials, according to the World Health Organization (WHO). The Gilead Sciences, Oxford University's researchers, and Moderna, an American biotech company, are the top players in the race of the Covid-19 vaccine. Globally there has been major Coronavirus vaccine updates: Anhui Zhifei Longcom, A Chinese Company, began Phase II trials.Medicago, A Canadian based company, announced a Pase I trialCanSino Biologics approved a vaccine for military use. The many trials that have reached Phase III: Moderna, American Company, is hoping to start it's phase II in July and wishes to have the doses of the vaccine ready by early 2021.The British-Swedish company AstraZeneca and the University of Oxford have developed a vaccine based on the traits of Chimpanzee adenovirus, which is called as ChAdOx1, This Vaccine is in its Phase II and III trials in England. While Phase III in Brazil and South Africa. Hope is that this project delivers emergency vaccines by October.Maryland-based Novavax, this company started its trials for a proposed Coronavirus vaccine in May. If the tests succeed, the company expects to deliver about 100 million doses for use in The United States by the first half of the year 2021.Sinopharm, a Chinese company, announced in June that it would be going to run its Phase III trials.The Murdoch Children's Research Institute in Australia is working with the Bacillus Calmette-Guerin vaccine, which was developed in the early 1900s as a protection against tuberculosis. They will be conducting a Phase III trial, and various other tests are underway to see if the vaccine partly protects against the coronavirus. Whereas, Zydu Cadila, an Indian Vaccine-Maker, has framed a DNA-based vaccine. They announced the approval of human trials on July 3. This is the second company in India to enter the Covid-19 vaccine race after Bharat Biotech. Also Read: \u092a\u0932\u091f\u0924\u0947 \u092c\u092f\u093e\u0928\u094b\u0902 \u0915\u0947 \u0938\u093e\u0925 \u092c\u093e\u092c\u093e \u0930\u093e\u092e\u0926\u0947\u0935 \u0915\u0940 \u0915\u094b\u0930\u094b\u0928\u093e \u0915\u0940 \u0926\u0935\u093e\u0908 \u0915\u093e \u0926\u093e\u0935\u093e \u091d\u0942\u0920\u093e? Bharat Biotech, in collaboration with the Indian Council of Medical Research and The National Institute of Virology, fabricated a vaccine called 'Covaxin.' This vaccine is engineered from the inactive rabies virus to carry proteins from the coronavirus. Phase I and II trials, will start this month. The Indian Council of Medical Research envisions to produce vaccines ready for public use by August 15, but this target has been met with cynicism.